Tempus
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
Tempus AI Q2 Revenues Rise 25 Percent in First Quarter as Public Company
The firm expects full-year 2024 revenues of about $700 million, representing growth of approximately 32 percent year over year.
TD Cowen, JP Morgan Initiate Coverage of Tempus AI With Buy, Overweight Ratings
Cowen said that Tempus is a differentiated oncology diagnostics company with an order backlog from pharma clients and the potential for strong growth and rising margins.
Tempus Nabs CMS Advanced Diagnostic Laboratory Test Status for Tumor Mutation Profiling Test
The xT CDx is a next-generation sequencing-based assay that is used for the detection of substitutions, insertions, and deletions and microsatellite instability status.
Top Five Articles on 360Dx Last Week: Roche Gets EUA, Inks Licensing Deal; FDA Clearances; More
Last week, readers were most interested in a story about Roche's four-in-one molecular test receiving Emergency Use Authorization from the FDA.